# TroFuse-011 (NCT06841354)

> A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06841354
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Triple Negative Breast Neoplasms
- Interventions: Sacituzumab tirumotecan; Pembrolizumab; Rescue Medication; Paclitaxel; Nab-paclitaxel; Gemcitabine; Carboplatin
- Enrollment: 1000
- Primary outcome: Progression-Free Survival (PFS) (sac-TMT versus treatment of physician's choice (TPC); sac-TMT plus pembrolizumab versus TPC)
- Primary outcome: Overall Survival (OS) (sac-TMT versus TPC)

## Indexed commentary on TroFuse-011 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trofuse-011-nct06841354